Navigation Links
Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
Date:6/24/2013

Portland, OR (PRWEB) June 24, 2013

Nonalcoholic steatohepatisis or NASH is a common, often "silent" chronic liver disease, occurring in people who drink little or no alcohol. Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins.

Fibrosis generally occurs at a low area percentage in tissue, and manual subjective evaluation cannot accurately discern discrete changes at low levels. To address this obstacle, Flagship's quantitative Tissue Image Analysis (tIA) method has been used to determine precise percentages of induced fibrosis in various experimental animal models. Results allowed discrimination of induction and therapy-related reductions in collagen levels at less than 5% increments, and these changes can only be measured accurately with computer-assisted pathology.  Data from tIA can be combined with histomorphologic and molecular data to allow greater utilization of animal tissue in antifibrotic drug development.

This quantitative approach of measuring fibrosis is being applied to different liver fibrosis-inducing models and in different species. This same approach has also been applied to measure fibrosis in cardiac and renal tissues and is being investigated for use in pulmonary fibrosis animal models.

Flagship's approach combines the expert knowledge of experienced scientists with innovations in digital pathology, leading to greater data accuracy and more efficient utilization of resources in drug development.

Flagship develops new tissue analysis endpoints for use in both research and CLIA clinical trials as part of their histology services.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10852679.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Clinovo, Leading CRO in the Bay Area, Endorsed by Medical Device Company for Their Flagship System: Clincapture
2. BioXcel Launches Its Flagship Product, PharmGPS™
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
8. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
11. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... 2016 ReportsnReports.com adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):